| COVID-19 |
1 |
1 |
| Brain |
0 |
0.66 |
| Blood-Brain Barrier |
0 |
0.53 |
| Dorsum |
0 |
0.41 |
| Wound Management |
0 |
0.3 |
| Major Depression |
0 |
0.26 |
| Canada |
0 |
0.25 |
| Post-Acute Sequelae of SARS-CoV-2 Infection |
0 |
0.25 |
| Viral Infection |
0 |
0.25 |
| Blood |
0 |
0.17 |
| Finger |
0 |
0.17 |
| Grant |
0 |
0.17 |
| Injury |
0 |
0.17 |
| Neuroinflammation |
0 |
0.17 |
| Depression |
0 |
0.15 |
| Healthcare and Medical Technology |
0 |
0.15 |
| Psychiatric Hospital |
0 |
0.12 |
| Biomarker |
0 |
0.08 |
| Clinical Research |
0 |
0.08 |
| Geriatrics |
0 |
0.08 |
| Hospital |
0 |
0.08 |
| Neurodegenerative Diseases |
0 |
0.08 |
| Neuroimaging |
0 |
0.08 |
| New York |
0 |
0.08 |
| Psychological Testing |
0 |
0.08 |